Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Abstract

BackgroundThe MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20–30 and AML30+ was made by regulatory agencies by initially restricting approval of azacitidine to AML20–30. Thus, uncertainty prevails regarding the diagnosis, prognosis and optimal treatment timing and strategy for patients with AML20–30. Here, we aim to provide clarification for patients treated with azacitidine front-line.MethodsThe Austrian Azacitidine Registry is a multicentre database (ClinicalTrials.gov: NCT01595295). For this analysis, we selected 339 patients treated with azacitidine front-line. According to the WHO classification 53, 96 and 190 patients had MDS-RAEB-I, MDS-RAEB-II and AML (AML20–30: n = 79; AML30+: n = 111), respectively. According to the FAB classification, 131, 101 and 111 patients had MDS-RAEB, MDS-RAEB-t and AML, respectively.ResultsThe median ages of patients with MDS and AML were 72 (range 37–87) and 77 (range 23–93) years, respectively. Overall, 80 % of classifiable patients (≤30 % bone marrow blasts) had intermediate-2 or high-risk IPSS scores. Most other baseline, treatment and response characteristics were similar between patients diagnosed with MDS or AML. WHO-classified patients with AML20–30 had significantly worse OS than patients with MDS-RAEB-II (13.1 vs 18.9 months; p = 0.010), but similar OS to patients with AML30+ (10.9 vs 13.1 months; p = 0.238). AML patients that showed MDS-related features did not have worse outcomes compared with patients who did not (13.2 vs 8.9 months; p = 0.104). FAB-classified patients with MDS-RAEB-t had similar survival to patients with AML30+ (12.8 vs 10.9 months; p = 0.376), but significantly worse OS than patients with MDS-RAEB (10.9 vs 24.4 months; p < 0.001).ConclusionsOur data demonstrate the validity of the WHO classification of MDS and AML, and its superiority over the former FAB classification, for patients treated with azacitidine front-line. Neither bone marrow blast count nor presence of MDS-related features had an adverse prognostic impact on survival. Patients with AML20–30 should therefore be regarded as having ‘true AML’ and in our opinion treatment should be initiated without delay.Electronic supplementary materialThe online version of this article (doi:10.1186/s13045-016-0263-4) contains supplementary material, which is available to authorized users.

Dyspnea, Fatigue, and Generalized Weakness in a 67-Year-Old Man: Approach to the Patient Between Guidelines and Clinical Judgment

“…On the other hand, in clinical trials, intensive chemotherapy and hypomethylating agents showed 11-13 and 7.7-12.6 months, respectively [13]. Historical approach to treatment focused on chronological age, nevertheless the age cut-offs for using aggressive treatment is likely biased by lesser intent to induce remission and local variability [14].…”

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia

“…In addition, mutations or aberrant expressions of genes including BCL2, NF-kB and MCL-1 have also been reported and are believed to be responsible for the FLT3 inhibitor resistance. Therefore, combinations of FLT3 inhibitors with other targeted therapies are interesting topics to be explored in the future (106,107).…”

The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

“…Таким образом, терапия ГМП может быть эффективной лечебной опцией у пациентов с МДС и ОМЛ с уровнем бластных клеток в костном мозге до 31 % [22]. Этот вывод не подтверждается в другом исследовании [23], в котором пациенты с уровнем бластных клеток 20-30 % имели худшие показатели ОВ, чем пациенты с уровнем бластных клеток менее 20 %. Влияние достижения ответа на ГМП и его сохра-нения до момента выполнения аллоТГСК не опреде-лено.…”